Crucial Role of Central Nervous System As a Viral Anatomical Compartment for HIV-1 Infection

Overview

Journal Microorganisms

Specialty Microbiology

Date 2021 Dec 24

PMID 34946138

Citations 6

Authors

Ana Borrajo

Valentina Svicher

Romina Salpini

Michele Pellegrino

Stefano Aquaro

Affiliations

Soon will be listed here.

Abstract

The chronic infection established by the human immunodeficiency virus 1 (HIV-1) produces serious CD4+ T cell immunodeficiency despite the decrease in HIV-1 ribonucleic acid (RNA) levels and the raised life expectancy of people living with HIV-1 (PLWH) through treatment with combined antiretroviral therapies (cART). HIV-1 enters the central nervous system (CNS), where perivascular macrophages and microglia are infected. Serious neurodegenerative symptoms related to HIV-associated neurocognitive disorders (HAND) are produced by infection of the CNS. Despite advances in the treatment of this infection, HAND significantly contribute to morbidity and mortality globally. The pathogenesis and the role of inflammation in HAND are still incompletely understood. Principally, growing evidence shows that the CNS is an anatomical reservoir for viral infection and replication, and that its compartmentalization can trigger the evolution of neurological damage and thus make virus eradication more difficult. In this review, important concepts for understanding HAND and neuropathogenesis as well as the viral proteins involved in the CNS as an anatomical reservoir for HIV infection are discussed. In addition, an overview of the recent advancements towards therapeutic strategies for the treatment of HAND is presented. Further neurological research is needed to address neurodegenerative difficulties in people living with HIV, specifically regarding CNS viral reservoirs and their effects on eradication.

Citing Articles

Characterization of HIV variants from paired Cerebrospinal fluid and Plasma samples in primary microglia and CD4 T-cells.

Gumbs S, Stam A, Mudrikova T, Schipper P, Hoepelman A, van Ham P J Neurovirol. 2024; 30(4):380-392.

PMID: 38713307 PMC: 11512886. DOI: 10.1007/s13365-024-01207-w.

Cognitive impairment and neurocognitive profiles among people living with HIV and HIV-negative individuals older over 50 years: a comparison of IHDS, MMSE and MoCA.

Chen P, Xin X, Xiao S, Liu H, Liu X, He N J Neurovirol. 2024; 30(2):103-114.

PMID: 38709469 DOI: 10.1007/s13365-024-01205-y.

Astrocytes: Role in pathogenesis and effect of commonly misused drugs in the HIV infected brain.

Pla-Tenorio J, Roig A, Garcia-Cesani P, Santiago L, Sepulveda-Orengo M, Noel Jr R Curr Res Neurobiol. 2023; 5:100108.

PMID: 38020814 PMC: 10663134. DOI: 10.1016/j.crneur.2023.100108.

Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive Review.

Borrajo A, Perez-Rodriguez D, Fernandez-Pereira C, Prieto-Gonzalez J, Agis-Balboa R Int J Mol Sci. 2023; 24(18).

PMID: 37762667 PMC: 10531836. DOI: 10.3390/ijms241814364.

Morphine suppresses peripheral responses and transforms brain myeloid gene expression to favor neuropathogenesis in SIV infection.

Fox H, Niu M, Morsey B, Lamberty B, Emanuel K, Periyasamy P Front Immunol. 2022; 13:1012884.

PMID: 36466814 PMC: 9709286. DOI: 10.3389/fimmu.2022.1012884.

References

Logsdon A, Erickson M, Rhea E, Salameh T, Banks W . Gut reactions: How the blood-brain barrier connects the microbiome and the brain. Exp Biol Med (Maywood). 2017; 243(2):159-165. PMC: 5788145. DOI: 10.1177/1535370217743766. View

Chai Q, Jovasevic V, Malikov V, Sabo Y, Morham S, Walsh D . HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration. Nat Commun. 2017; 8(1):1522. PMC: 5688069. DOI: 10.1038/s41467-017-01795-8. View

Honeycutt J, Wahl A, Baker C, Spagnuolo R, Foster J, Zakharova O . Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest. 2016; 126(4):1353-66. PMC: 4811134. DOI: 10.1172/JCI84456. View

Zhou L, Saksena N . HIV Associated Neurocognitive Disorders. Infect Dis Rep. 2014; 5(Suppl 1):e8. PMC: 3892625. DOI: 10.4081/idr.2013.s1.e8. View

Zucchini S, Pittaluga A, Brocca-Cofano E, Summa M, Fabris M, De Michele R . Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders. Neurobiol Dis. 2013; 55:110-9. DOI: 10.1016/j.nbd.2013.02.004. View

Becker J, Snitz B . Yes, it is time to reconsider how we rate cognitive impairments in HIV disease. Neuroepidemiology. 2013; 41(3-4):217-8. PMC: 3872990. DOI: 10.1159/000355128. View

Eggers C, Arendt G, Hahn K, Husstedt I, Maschke M, Neuen-Jacob E . HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol. 2017; 264(8):1715-1727. PMC: 5533849. DOI: 10.1007/s00415-017-8503-2. View

Thurgur H, Pinteaux E . Microglia in the Neurovascular Unit: Blood-Brain Barrier-microglia Interactions After Central Nervous System Disorders. Neuroscience. 2019; 405:55-67. DOI: 10.1016/j.neuroscience.2018.06.046. View

Saylor D, Dickens A, Sacktor N, Haughey N, Slusher B, Pletnikov M . HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. Nat Rev Neurol. 2016; 12(4):234-48. PMC: 4937456. DOI: 10.1038/nrneurol.2016.27. View

10.

Aquaro S, Panti S, Caroleo M, Balestra E, Cenci A, Forbici F . Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J Leukoc Biol. 2000; 68(3):429-35. View

11.

Gong Y, Chowdhury P, Nagesh P, Rahman M, Zhi K, Yallapu M . Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci Rep. 2020; 10(1):3835. PMC: 7052245. DOI: 10.1038/s41598-020-60684-1. View

12.

Torres-Munoz J, Nunez M, Petito C . Successful application of hyperbranched multidisplacement genomic amplification to detect HIV-1 sequences in single neurons removed from autopsy brain sections by laser capture microdissection. J Mol Diagn. 2008; 10(4):317-24. PMC: 2438200. DOI: 10.2353/jmoldx.2008.070074. View

13.

Shin A, Thayer S . Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol Cell Neurosci. 2012; 54:22-9. PMC: 3622188. DOI: 10.1016/j.mcn.2012.12.005. View

14.

Fois A, Brew B . The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication. Curr HIV/AIDS Rep. 2015; 12(2):299-303. DOI: 10.1007/s11904-015-0257-9. View

15.

Stockton P, Tacoronte N, Roberts B, Maronpot R, Petito C . Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture microdissection. J Neuropathol Exp Neurol. 2001; 60(9):885-92. DOI: 10.1093/jnen/60.9.885. View

16.

Harrington P, Schnell G, Letendre S, Ritola K, Robertson K, Hall C . Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009; 23(8):907-15. PMC: 3089803. DOI: 10.1097/QAD.0b013e3283299129. View

17.

Ohagen A, Devitt A, Kunstman K, Gorry P, Rose P, Korber B . Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol. 2003; 77(22):12336-45. PMC: 254258. DOI: 10.1128/jvi.77.22.12336-12345.2003. View

18.

Pollicita M, Muscoli C, Sgura A, Biasin A, Granato T, Masuelli L . Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line. BMC Neurosci. 2009; 10:51. PMC: 2694812. DOI: 10.1186/1471-2202-10-51. View

19.

Aquaro S, Borrajo A, Pellegrino M, Svicher V . Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages. Virulence. 2020; 11(1):400-413. PMC: 7219522. DOI: 10.1080/21505594.2020.1760443. View

20.

Marban C, Forouzanfar F, Ait-Ammar A, Fahmi F, El Mekdad H, Daouad F . Targeting the Brain Reservoirs: Toward an HIV Cure. Front Immunol. 2016; 7:397. PMC: 5044677. DOI: 10.3389/fimmu.2016.00397. View